-
Li Yan, president of Qilu Pharmaceutical Group, accompanied Lu Lin and his party to visit the enterprise
Time of Update: 2022-10-02
Li Yan, President of Qilu Pharmaceutical Group, expressed a warm welcome to the arrival of Lu Lin and his party, accompanied by Lu Lin and his party, Lu Lin and his party visited the exhibition hall of Qilu Pharmaceutical Enterprise, CMC R&D platform and intelligent manufacturing production workshop, and deeply and comprehensively understood the development process, industrial layout, corporate culture construction, drug research and development of the enterprise.
-
Philips Medical visited PeriTech for cooperation and exchange
Time of Update: 2022-10-02
On August 5th, Philips Medical Team visited Guangzhou Company, a well-known remote collaboration SaaS service provider in China, and Zhang Xiaofeng, CTO of PeriTech and Zhang Haiying, General Manager
-
Pharmaceutical machine enterprises have increased investment in research and development, and product performance and capacity expansion are accelerating
Time of Update: 2022-10-02
Pharmaceutical machinery enterprises increase investment, product performance and capacity expansion continue to accelerate (picture source: pharmaceutical network) It is worth mentioning that a number of pharmaceutical companies have invested more than 1 billion yuan in innovation, in addition to the above-mentioned BeiGene Shenzhou, China Biopharmaceuticals, including Hengrui, Junshi Biologics, CSPC, and Huang Pharmaceutical.
-
Pfizer sold the factory, Suqiao was acquired, Kewang "optimized production capacity", and the self-built factory building was "not fragrant"?
Time of Update: 2022-10-02
Earlier, WuXi Biologics CEO Chen Zhisheng once said: "Some companies have built factories that exceed their own needs or capabilities, and now there is a 'factory building tide' in China, what will be the situation in five years?" ” China's biomedical industry is developing rapidly, and in recent years, many enterprises have increased their efforts to build their own factories and expand production capacity.
-
Advance Media's interim results: Strong growth of the business twin engines, strong marketing system to promote the full commercialization
Time of Update: 2022-10-02
Key Operating Summary: Despite the impact of the epidemic in the first half of the year, sales of transcatheter valve therapy business and neurointervention business were strong, with revenue of RMB52.
-
Under the acceleration of aging, it may stimulate the innovation and upgrading of drugs and devices
Time of Update: 2022-10-02
Under the acceleration of aging, it may stimulate drugs and devices to accelerate innovation and upgrading (Source: Pharmaceutical Network) The demand for innovative drugs will continue to increase in the future The demand for innovative drugs will continue to increase in the future After the human body enters old age, the function declines, including cardiovascular and cerebrovascular diseases, diabetes, tumors and other diseases will increase, and the demand for related treatment new drugs will also increase.
-
The invested enterprise of Huaxing Medical Industry Fund, Oppmai, landed on the science and technology innovation board and opened sharply on the first day
Time of Update: 2022-10-02
On September 2, Shanghai Opmeg Biotechnology Co. , Ltd. (hereinafter referred to as "Opme"), known as the first share of cell culture media in China, officially landed on the Science and Technology I
-
【CDE Acceptance Fact Sheet】An overview of CDE acceptance from September 12 to September 18
Time of Update: 2022-10-02
The status of acceptance of the consistency evaluation is as follows: There are 29 acceptance numbers for Class 1 drugs, including 23 chemical drugs and 6 therapeutic biological products.
-
This 10 billion market will be impacted by a large number of blockbuster new drugs!
Time of Update: 2022-10-02
In the national collection, many varieties of drugs for the treatment of diseases related to gastric acid secretion have been won by domestic enterprises, such as in the aluminum magnesium carbonate market, in 2021, Chongqing Huasen Pharmaceutical won the bid, and Pfizer lost its qualifications; In the esomeprazole market, the original research AstraZeneca has not entered the collection, which has affected the continuous decline in market share.
-
Zhongying Biologics Standard-grade Reagents were unveiled, and the application of NK cell tumor therapy received attention from the industry
Time of Update: 2022-10-02
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology Zhongying Bio's drug standard grade NK/CAR-NK cell amplification reagent will be displayed during the conference, Zhongying Bio has independent intellectual property rights based on IL21 trophoblast cell preparation NK cell method relative to other ways to be stable, the prepared final product effector cells can basically reach more than 90% purity, and the expansion multiple is high, the killing function is strong.
-
The ten-billion-level industry is taking off, how to join the company?
Time of Update: 2022-10-02
Chronic diseases have always been characterized by long disease course, complex etiology, many sick people, health damage and serious social harm; Chronic disease management is a system engineering that needs to be professionalized and customized.
-
In September, a large number of medical consumables ushered in a wave of price cuts
Time of Update: 2022-10-02
According to the "Announcement", the scope of the simulation declaration of the purchase of this volume includes ultrasonic knife heads, intraocular lenses, and enterprises participating in the declaration of this procurement of the amount of the belt should strictly follow the national provincial platform minimum purchase of the selected registration certificate or single product specifications and models to declare the products participating in the procurement of the quantity.
-
Kangtai Biotech won the "2021 China Biomedical Enterprises Top 10"
Time of Update: 2022-10-02
On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List". Shenzhen Kangtai Biological Products Co. , Ltd. (sto
-
Semi-annual report observation: the performance of pharmaceutical machinery enterprises in the first half of the year increased, but the number of institutional positions decreased
Time of Update: 2022-10-02
At present, listed pharmaceutical equipment companies have basically disclosed their 2022 semi-annual reports, and overall, most of the company's performance has achieved growth. However, the author n
-
The prosperity of pharmaceutical and other industries is good, and the performance of many pharmaceutical companies in the first three quarters is pre-gratifying
Time of Update: 2022-10-02
0985 million yuan; Kaipu Bio expects net profit in the first three quarters to increase by 108.
0985 million yuan; Kaipu Bio expects net profit in the first three quarters to increase by 108.
-
The price of medicinal herbs has risen again? The reasons are complex and diverse
Time of Update: 2022-10-02
In addition to objective factors, artificial hoarding speculation is also an important influencing factor for the price increase of medicinal materials, especially the main catalyst for the price increase of rigid Chinese herbal medicine categories.
-
Gu Yitang was approved by the Ministry of Education for the 2022 "Industry-University Cooperation and Collaborative Education" project
Time of Update: 2022-10-02
Red Net Moment News September 2 (Correspondent Yuan Wenbin) On August 26, 2022, the Ministry of Education announced the industry-academia cooperation collaborative education project guide through the
-
Notice on the Special Activities of Healthy China Action on Health Promotion of Traditional Chinese Medicine
Time of Update: 2022-10-02
Provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps Health China Action Promotion Office, Health Commission, and Bureau
-
Ovarian cancer targeted drug Nirapali Chinese patients first-line whole population maintenance therapy research data released!
Time of Update: 2022-10-02
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in the Chinese population The PRIME study showed that first-line maintenance therapy with the ovarian cancer target drug Nirapalil had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, with median progression-free survival of 24.
-
Pharmaceutical companies have joined hands to jointly research new drugs, and the results are constantly emerging
Time of Update: 2022-10-02
Recently, the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP) recommended the approval of Beyfortus, jointly developed by Sanofi and AstraZeneca, for use in newborns and infants to help prevent RSV lower respiratory tract infections as the first respiratory syncytial virus (RSV) season arrives.
